TCRT Stock Explodes As Velaris Deal Redraws The Map

Alaunos Therapeutics Inc. stocks have been trading up by 26.61 percent amid heightened optimism over its cancer immunotherapy pipeline.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TCRT

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Alaunos Therapeutics completed the Velaris Therapeutics acquisition, adding ActRII-Fc ligand traps and biologics for pulmonary arterial hypertension and related cardiopulmonary diseases.
In tandem with the Velaris deal, the company raised about $350M in a private placement, extending its cash runway into 2029.
The new capital is earmarked to push several Velaris-derived drug candidates through clinical proof-of-concept and initial regulatory filings.
Development of lead asset VLR199 for pulmonary arterial hypertension is a central focus for the freshly raised funding.
After the acquisition and financing news, TCRT shares spiked roughly 126% to about 225% on extremely heavy trading volume.

Live Update At 07:46:51 EDT: On Friday, October 16, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 26.61%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TCRT has traded like a completely different stock since the Velaris news hit. Alaunos Therapeutics Inc. spent weeks stuck under $1, closing at $0.78–$1.27 for most of the recent daily tape. Then, on 2026/10/12, TCRT closed at $1.05. The next three sessions turned into a rocket ride, with closes of $3.03, $2.07, and $2.18 as traders digested the Velaris deal and $350M raise.

The intraday 5‑minute chart shows tight action in the $2.80–$3.10 zone, signaling heavy two-way trading as momentum players and profit-takers battle it out. That kind of thick tape is what short-term traders look for: liquidity, clear levels, and emotional order flow.

Under the hood, Alaunos Therapeutics still looks like a classic high-risk biotech. TCRT posted just $5,000 in revenue and a quarterly net loss of about $952,000, with negative return metrics across the board and a current ratio of 0.8 before the new financing. Price-to-sales sits near 957x on that tiny revenue base, telling traders this is a story almost entirely about future pipeline value.

More Breaking News

The key shift now is that the $350M private placement, if managed well, stretches the cash runway to 2029 and gives TCRT real time to try to turn that story into data.

Why Traders Are Watching TCRT After The Velaris Deal

The Velaris acquisition is not a small tweak for Alaunos Therapeutics Inc.; it is a reset. Before this move, TCRT was a thinly traded, cash-strained biotech fighting negative returns and minimal revenue. With Velaris on board, the company now owns a cardiopulmonary pipeline built around ActRII-Fc ligand traps and biologics targeting pulmonary arterial hypertension (PAH) and related diseases.

For traders, that pipeline plus cash is the entire pitch. The company locked in about $350M of fresh capital in a private placement of Series C non‑voting convertible preferred stock alongside the deal. Management says this extends the cash runway to 2029 and should fund multiple candidates, including lead asset VLR199 for PAH, through proof-of-concept and initial regulatory filings. In trading terms, that means a multi‑year window packed with binary clinical catalysts.

The tape already told you this matters. TCRT ripped between roughly 126% and about 225% on extremely heavy volume once the Velaris transaction and financing were confirmed. That kind of move does not happen without aggressive speculative money crowding in.

But veteran traders in the Tim Sykes community will also note the catch. Those convertible preferred shares represent potential future dilution. If TCRT executes, the market may absorb it. If trials disappoint, that same structure can weigh hard on the common. So the new Alaunos Therapeutics story is powerful, but it is also polarized: either the Velaris pipeline delivers, or the air comes out of this balloon.

Conclusion

TCRT has transformed from a quiet sub‑$1 biotech into a front-page momentum ticker almost overnight. Alaunos Therapeutics used the Velaris Therapeutics acquisition to grab a whole new cardiopulmonary pipeline and then backed it with a $350M private placement that, on paper, funds operations into 2029. For traders, that combination of assets, time, and fresh cash is exactly what fuels big speculative runs.

The daily and intraday charts now show classic momentum behavior: a sharp gap higher, broad trading ranges, and thick liquidity around key intraday levels. Short-term traders will watch how TCRT handles pullbacks toward prior support and whether volume stays elevated once the initial Velaris headline buzz fades. In this kind of fast-moving environment, it’s crucial to remember the importance of patience and price discipline. As Tim Bohen, lead trainer with StocksToTrade says, “I never chase price. The best opportunities allow me to enter on my terms, not when I’m feeling pressured.” That mindset helps traders avoid emotional entries in the middle of extended moves.

Fundamentally, Alaunos Therapeutics Inc. is still early stage, with minimal revenue and deep losses, so the entire bull case revolves around turning VLR199 and the rest of the Velaris pipeline into real clinical wins. That is why rule number one from Tim Sykes applies here: “Cut losses quickly, because any one trade can always go against you.” TCRT offers a textbook lesson for traders in how a single strategic deal and a massive financing can reset a stock’s risk-reward — and why discipline matters even more once the fireworks start.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!